In January 2026, following the dissemination of the scientific preprint on the cell therapy REMaST published in the international scientific journal Immunity by Cell Press,Hemera received significant national media coverage, confirming the growing interest in innovative solutions within the field of regenerative medicine and advanced therapies.
The preclinical data, demonstrating the ability to functionally reprogram macrophages by transforming them from inactive immune cells into active drivers of regenerative processes in the nervous system, represent a relevant advancement in the landscape of cell therapies for the treatment of spinal cord injuries. This approach, based on the proprietary REMaST platform, positions itself as a potentially innovative paradigm in therapeutic strategies for neurodegenerative and traumatic conditions.
The scientific relevance of the results was covered by leading news outlets and press agencies, including ANSA, Il Sole 24 Ore Radiocor, and Rai News, contributing to increasing Hemera’s visibility within the Italian biotech ecosystem. In the field of science communication, Popular Science Italia and Quotidiano Sanità further explored the translational potential of the REMaST technology, highlighting its clinical implications.
Particular attention was also given by the TG3 Leonardo television program, which emphasized the innovative value of the research and its potential applications in the context of central nervous system regeneration. Coverage was further reinforced by numerous other national and local media outlets, including L’Arena, La Presse, Juorno, InSalute, reflecting widespread and cross-sector interest.
“The attention received from national media is a recognition of the long-standing work of our team and a confirmation of the social and scientific value of our mission,” said Cristiana Vingoli CEO of Hemera. “As we approach the publication of the full manuscript in Immunity on February 10, our commitment remains focused on advancing toward the clinical phase, with the aim of translating this scientific discovery into a concrete therapeutic solution for patients.”
REMaST® on the cover of Immunity and growing media resonance
In February 2026, following the publication of the full preclinical dataset in Immunity by Cell Press on February 10 and its selection for the journal cover, media interest in Hemera and the REMaST platform continued to grow, further consolidating the company’s position in the international biotech landscape.
The announcement received additional coverage from leading industry outlets and science-business platforms, including Wired Italia, Open Innovation Regione Lombardia, and Clic Medicina, which explored the potential of REMaST technology in the field of advanced therapies and regenerative medicine.
Rassegna Business published an interview with Cristina Vignoli, CEO of Hemera, who highlighted the transformative nature of the approach: “The discovery made by Hemera’s scientists shows that certain immune cells, under controlled conditions, can become powerful allies in the regeneration of nervous tissue, opening a potential breakthrough in regenerative medicine.”
Additional scientific and editorial coverage was published by media and radio platforms such as Unica Radio, as well as digital outlets including Modernews and Futuro Prossimo, confirming a growing interest that spans not only the scientific community but also the fields of innovation and economics, highlighting the disruptive nature of the REMaST platform in regenerative medicine and next-generation cell therapies.
In particular, Innlifes highlighted the groundbreaking biological rationale behind the technology, reporting the words of Prof. Massimo Locati: “In our work we demonstrated that macrophages can be ‘educated’ to promote the regeneration of nervous tissue, acting on the immune environment of the lesion and opening new therapeutic perspectives.”
From TG3 Leonardo and TG4 Medicina to Touchpoint: REMaST® in the March press review
Approximately one month after the publication in Immunity by Cell Press, media interest in REMaST continues to grow, with new insights from national outlets and scientific media reinforcing the platform’s visibility in the field of regenerative medicine.
Key contributions in March include interviews with Ilaria Decimo, Co-Founder and Director of Research & Development at Hemera, aired on Smart City (Radio 24) and TG4 Medicina. In both appearances, Decimo explained the biological rationale behind REMaST, describing the role of “educated” macrophages in central nervous system regeneration and the therapy’s potential to promote nerve regrowth and remodeling of the lesion microenvironment.
A further in-depth analysis was published by Osservatorio Terapie Avanzate, focusing on the scientific genesis of the platform and its immunological and translational approach. A forthcoming article in Le Scienze (the Italian edition of Scientific American) is also expected, further confirming the growing attention from international science communication outlets.
The month also includes Touchpoint Magazine, an editorial platform of Oltre La Media Group focused on the dynamics between companies, markets, and industrial development, published an in-depth article in its February–March issue on REMaST, exploring its potential clinical and socio-economic impact in spinal cord injuries, with particular attention to the epidemiological relevance of the condition and the need for innovative therapeutic solutions.
As highlighted by Cristiana Vignoli: “Responsibility means creating the conditions for an innovation to become a concrete clinical pathway in the shortest possible time.”
Hemera is focusing on advancing clinical development and translating scientific evidence into potential therapeutic solutions for patients.